Feidhmeannacht na Seirbhíse Sláinte,
Seirbhís Aisíocha Príomhchúraim
Plás J5, Lárionad Gnó na Páirce Thuaidh, Bealach Amach 5, M50, An Bóthar Thuaidh, Fionnghlas, Baile Átha Cliath 11, D11 PXT0

Primary Care Reimbursement Service
J5 Plaza, North Park Business Park, Exit 5, M50, North Road, Finglas, Dublin 11, D11 PXT0

www.pcrs.ie

t 01 8647100
e PCRS@hse.ie

15th December 2025

Circular 022/25

RE: Victoza® 6mg/ml solution for injection in pre-filled pen (liraglutide) Discontinuation

Dear Doctor,

The Health Products Regulatory Authority (HPRA) has requested the support of PCRS in distributing this Medicine Shortage Communication again to GPs, as the planned date for market cessation of Victoza® 6mg/ml solution for injection in pre-filled pen (liraglutide) is imminent.

Yours faithfully,



Shaun Flanagan
Primary Care Reimbursement Service

Medicine Shortage Communication

September 2025

Victoza® 6 mg/mL solution for injection in pre-filled pen (liraglutide): Risk of supply shortage due to marketing cessation (discontinuation)

Dear Healthcare Professional,

Novo Nordisk Ireland in agreement with the European Medicines Agency (EMA) and the Health Products Regulatory Authority (HPRA) is notifying healthcare professionals about the marketing cessation (discontinuation) of Victoza® (liraglutide) in all EU/EEA countries. This discontinuation may lead to short-term intermittent shortages in some countries.

Overview of situation

- **Novo Nordisk will discontinue the marketing of Victoza® across the EU/EEA.**
- **Due to the marketing cessation, there may be a risk of short-term intermittent shortages in some countries until the product is no longer marketed.**
- **The discontinuation in Ireland will occur on 31 December 2025.**
- **The marketing cessation is for commercial reasons and not a consequence of any safety or quality related issue.**

Mitigation measures

Novo Nordisk is engaging with the European Medicines Agency and the HRPA on mitigation measures.

Regulatory authorities, physicians, healthcare providers and patient organisations are being informed to help ensure patients transition safely to alternative options for continuity of care.

Patients need to be switched to an alternative treatment in time to avoid the risk of missing doses, which may lead to serious clinical consequences.

Healthcare professionals (HCPs) should consider the following mitigation measures:

- No new patients should be started on Victoza®.
- HCPs should switch all patients who are currently on Victoza® to alternative GLP-1 analogues or other alternative medication based on existing guidance and clinical judgement.
- HCPs are requested to follow the relevant summary of product characteristics (SmPCs) of the alternative products for dosing recommendations while switching patients to alternative products.
- HCPs are requested to provide clear instructions of usage to the patient, if switched to alternative GLP-1 analogue or other alternative.
- Close glucose monitoring is recommended during the switch to another type or brand of alternative GLP-1 analogue or other alternative and patients should be fully informed about any relevant changes.

Background information

Victoza® [1] is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

• as monotherapy when metformin is considered inappropriate due to intolerance or contra indications;

• in addition to other medicinal products for the treatment of diabetes

Call for reporting

Adverse events including medication errors relating to Victoza® ® should be reported to the Novo Nordisk Safety Department at complaintireland@novonordisk.com or Tel: 01 8629700 or to the Health Products Regulatory Authority at www.hpra.ie.

Company contact point

Further information can be obtained by contacting Novo Nordisk Limited, Ireland on 01 8629700 or infoireland@novonordisk.com.

Yours sincerely,



Dr. Donna Sexton
Clinical, Medical and Regulatory Director
Novo Nordisk Limited, Ireland

References

1. Victoza | European Medicines Agency (EMA)

www.medicines.ie

Date of preparation: Sep 2025, IE25VZ00003